Potential treatment sequencing approach for MPC in 2017?
FOLFIRINOX
Nab-paclitaxel +
gemcitabine
(if no neuropathy
)
Gemcitabine
FOLFIRINOX
Nab-paclitaxel +
gemcitabine
MM-398 +
5-FU/LV
OFF
Capecitabine
MM-398 + 5-FU/LV
(depending on
prior exposure)
1
st
line
2
nd
line
3
rd
line
NOTE: Nab-paclitaxel is licensed for use in combination with gemcitabine as
1
st
-line therapy for patients with MPC
Nab-paclitaxel?
(depending on
prior exposure)
mFOLFOX6 or CAPOX
Platinum-based tx
(depending on
prior exposure)
Supported by RCT data
Supported by retrospective data or small,
single arm trials
5-FU
